Antigen presentation by B7-nonprofessional APC does not prevent responses to solid tumor cells

Area of Science:

• Immunology
• Oncology
• Virology

Background:

• Tumor growth in vivo is often linked to immune suppression.
• The study investigates the impact of antigen expression by tumor cells on antitumor immunity.
• It explores whether initial antigen presentation by tumors affects subsequent immune responses.

Purpose of the Study:

• To determine if expressing a known antigen in tumor cells inhibits antitumor responses.
• To assess if this inhibition can be overcome by subsequent appropriate antigen presentation.
• To understand the role of antigen presentation context in immune evasion and response.

Main Methods:

• Solid tumor cells were engineered to express a surrogate tumor antigen, the nucleoprotein (NP) of the PR8 virus.
• Mice bearing these NP+ tumor cells were monitored for tumor rejection and cytotoxic T lymphocyte (CTL) responses in vitro.
• T cell differentiation and tumor regression were assessed following subsequent inoculation with the PR8 virus.

Main Results:

• NP+ tumor cells were not rejected in vivo and did not stimulate detectable CTL responses in vitro.
• T cells from these mice differentiated into CTLs after PR8 virus inoculation.
• Tumors in these mice regressed following viral inoculation, indicating a restored antitumor response.

Conclusions:

• Prior presentation of tumor antigens by tumor cells does not necessarily prevent an immune response.
• The context and timing of antigen presentation are critical for eliciting effective antitumor immunity.
• Immune tolerance induced by tumor antigen expression can be overcome by appropriate subsequent antigen presentation.